Radiopharm Theranostics (RADX) Accumulated Expenses (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Accumulated Expenses for 2 consecutive years, with $450104.0 as the latest value for Q2 2025.
- Quarterly Accumulated Expenses rose 12.59% to $450104.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $450104.0 through Jun 2025, up 12.59% year-over-year, with the annual reading at $450104.0 for FY2025, 12.59% up from the prior year.
- Accumulated Expenses for Q2 2025 was $450104.0 at Radiopharm Theranostics, up from $399788.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $450104.0 in Q2 2025, with the low at $399788.0 in Q2 2024.